Skip to main content
OpenTrials
Completed

NCT Number: NCT02288832

Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by "Point-of-care" During Pregnancy

Infection is the principal cause of preterm births. Most (90%) women with preterm deliveries have no abnormal history. It is widely agreed that preterm delivery is often associated with bacterial vaginosis. One of the major difficulties at this time is that the diagnosis of bacterial vaginosis is based on heterogeneous criteria. The technique currently used is the Nugent score, but it lacks the characteristics necessary for widespread use in the general population. It must be performed on a fresh swab, and any delay in transporting it can cause drying that makes the test difficult to perform.

The investigators have developed a rapid diagnostic tool for bacterial vaginosis using molecular biology based on a point of care model and obtained a patent (European Patent Office N° 2087134). In comparison with the reference techniques, our tool's performance has been excellent, in terms of specificity, sensitivity, and positive and negative predictive values. In particular, our work showed that 57% of the flora samples rated as intermediate on the Nugent score were in reality true bacterial vaginosis. Molecular biology therefore identifies a homogeneous population of women with vaginal flora anomalies. The investigators recently showed that the carriage of Atopobium vaginae and/or Gardnerella vaginalis >105/mL shortens the time to delivery in a population at risk of preterm delivery (PHRC 2006). Vaginal flora anomalies are therefore an important target for preventing preterm delivery.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Low Risk of Preterm Delivery

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Assistance Publique Hopitaux de Marseille, Marseille, France

Loading trial locations.

About this study

The principal objective is to use a cost-effectiveness study to assess the medical and economic impact of a new strategy for the screening and subsequent treatment of vaginal flora anomalies before the 20th week of gestation- molecular biology techniques (PCR for A. vaginae and G. vaginalis by point-of-care testing) will test self-collected vaginal samples in a population of pregnant women at low risk of preterm delivery. There are multiple secondary objectives, including assessment of the effect of the strategy on the following indicators- delivery before 26, 32, and 37 weeks. Methods-An open-label prospective randomized study will compare 2 groups with different management of their pregnancies. Pregnant women at low risk, regardless of any symptoms, will be randomized into 2 groups. The study will not include women at high risk of preterm delivery. Innovative strategy (group A)- these women will undergo routine screening for bacterial vaginosis by analysis of their self-collected vaginal samples with this innovative technique.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women over 18 years with a pregnancy before 20 weeks are some parity and gravidity;
  • Woman who understood the process and the objectives of the study and who agreed to sign an informed consent;
  • Without a history of premature birth or late abortion (population at low risk of preterm birth);
  • Having no major risk factors for prematurity: insulin-dependent diabetes, systemic lupus erythematosus, hypertension, uterine malformation, cone biopsy, multiple pregnancy;
  • No pre-existing hypertension;
  • Asymptomatic or symptomatic regarding the diagnosis of bacterial vaginosis.

Exclusion criteria

  • Woman withdrawing her consent during the study

Treatment and study plan

-self-collected vaginal samples

Other

zithromax

Drug

Other names: azithromycine

usual practices

Other

Primary outcomes

  1. the incremental cost-effectiveness

    Time frame: 30 months

    the incremental cost-effectiveness ratio between the two groups corresponding to the cost of preterm birth before 37 avoided.

    • average differential effect in terms of preterm birth before 37 weeks of 0.013. A preterm birth rate of 0.043 (+/- 0.043) is expected in the group B and 0.03 (+/- 0.03) in Group A;
    • Cost differential means € 230 +/- 35. This difference takes into account the estimated EFC (initial and recurrent) cost and estimated cost of treatments vaginosis cases (10% of patients);
    • Cost-effectiveness threshold of 22,500 euros corresponding to the average cost ratio that is could avoid caring for a child born prematurely before 37 weeks as documented in the international literature (Petrou 2012);

Secondary outcomes

  1. the delivery rate before 26, 28, 32 and 37 weeks

    Time frame: 30 months

  2. the rate of rupture of membranes

    Time frame: 30 months

  3. the rate of intrauterine growth retardation

    Time frame: 30 months

  4. the rate of endometritis

    Time frame: 30 months

  5. the preterm birth rate adjusted

    Time frame: 30 months

  6. he total duration of hospitalization and earlier for postpartum mother and newborn in number of days

    Time frame: 30 months

Sponsors and collaborators

Lead sponsor

Assistance Publique Hopitaux De Marseille

Other

Registry information

Acronym: AuTop

Important dates

Study start
2015
Primary completion
2018
Study completion
2022
First posted
Nov 11, 2014
Registry last updated
Apr 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.